Document Detail

Influence of aprotinin on early graft thrombosis in patients undergoing myocardial revascularization.
MedLine Citation:
PMID:  7535064     Owner:  NLM     Status:  MEDLINE    
One hundred sixty-five patients undergoing primary myocardial revascularization were prospectively entered into a randomized, double-blind, placebo-controlled study, in a single institution, in order to determine the influence of high- and low-dose aprotinin application on early coronary artery bypass graft patency. All patients were operated on by the same team and the three treatment groups were comparable in all demographic data and surgical variables. Postoperative chest tube drainage and transfusion requirements were significantly reduced in patients receiving high or low doses of aprotinin. In all patients vein and internal mammary artery graft patency was assessed by control coronary angiograms 4 to 15 days (median 8.2 days) postoperatively. In the high-dose aprotinin group, 140 of 142 vein grafts and in the low-dose aprotinin group all of the 128 vein grafts were patent compared with 138 of 139 in the placebo group. The difference was not statistically significant (P > 0.05). All pedicled internal mammary artery grafts were patent in the three treatment groups. The prevalence of perioperative myocardial infarction was evaluated by serial creatine kinase-myocardial band (CK-MB) isoenzyme measurements and by electrocardiographic recordings. No additional changes that could be attributed to aprotinin were observed. In conclusion, these results suggest that perioperative myocardial infraction secondary to aprotinin-induced native coronary artery or conduit thrombosis is not increased by aprotinin in patients undergoing primary myocardial revascularization.
A Kalangos; G Tayyareci; R Prêtre; P Di Dio; O Sezerman
Related Documents :
10955744 - Surgical treatment for graft stenosis after repair of an interrupted aortic arch: repor...
305234 - Prophylactic use of intra-aortic ballon pump in aortocoronary bypass for patients with ...
10158384 - Recanalization of chronically occluded aorto-coronary vein grafts.
22865314 - Cardiac sarcoidosis masquerading as syncope with right ventricular septal mass.
9083884 - Is the brugada syndrome a distinct clinical entity?
24820764 - Cardioprotective effects of phosphocreatine on myocardial cell ultrastructure and calci...
Publication Detail:
Type:  Clinical Trial; Journal Article; Randomized Controlled Trial    
Journal Detail:
Title:  European journal of cardio-thoracic surgery : official journal of the European Association for Cardio-thoracic Surgery     Volume:  8     ISSN:  1010-7940     ISO Abbreviation:  Eur J Cardiothorac Surg     Publication Date:  1994  
Date Detail:
Created Date:  1995-05-01     Completed Date:  1995-05-01     Revised Date:  2004-11-17    
Medline Journal Info:
Nlm Unique ID:  8804069     Medline TA:  Eur J Cardiothorac Surg     Country:  GERMANY    
Other Details:
Languages:  eng     Pagination:  651-6     Citation Subset:  IM    
Cardiovascular and Thoracic Surgery Center of Istanbul, Haydarpasa, Turkey.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Aprotinin / administration & dosage*,  therapeutic use
Coronary Angiography
Coronary Artery Bypass / adverse effects
Creatine Kinase / blood
Dose-Response Relationship, Drug
Double-Blind Method
Graft Occlusion, Vascular / prevention & control*,  radiography
Middle Aged
Myocardial Revascularization* / adverse effects
Postoperative Complications / prevention & control*
Prospective Studies
Vascular Patency / drug effects
Reg. No./Substance:
0/Isoenzymes; 9087-70-1/Aprotinin; EC Kinase

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Phenotype and differentiation potential of a novel rat tracheal epithelial cell line.
Next Document:  Glycosylation of recombinant human granulocyte colony stimulating factor: implications for stability...